Home / Stock ratings / Healthcare Stocks / JNJ
Stock rating · Pharmaceutical Preparations
Johnson & Johnson (JNJ) Stock Rating & Analysis
As of October 7, 2026, MELANY rates Johnson & Johnson 65 out of 100 (Hold). Its highest factor score is catalyst setup at 100, and its lowest is valuation at 40.
MELANY ratingRated 2026-10-07JNJ · composite score
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare company, organized into two divisions, innovative medicine and medtech, which represent all of its sales after the 2023 divestment of its consumer business, Kenvue. Following 2023-24 restructurings, its drug division focuses on immunology, oncology, and neurology, and just over half of total revenue is generated in the United States.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How JNJ's rating has moved
- 0Past week, since Sep 30: score held at 65.
- +3Past four weeks, since Sep 9: score rose 3 points to 65.
Weekly points: Sep 9: 62 · Sep 16: 65 · Sep 23: 65 · Sep 30: 65 · Oct 7: 65 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why JNJ scores 65/100
JNJ's 8 factor scores run from 40 to 100, and 3 of them sit above its composite of 65. Here is how JNJ breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 21.1x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 68%
- ROE 26%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Earnings in 6 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 6 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How JNJ compares
As of October 7, 2026, Johnson & Johnson is tied for 14th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for JNJ
- Earnings report in 6 days, binary outcome can move 10%+ either way
Sector and theme context
Johnson & Johnson sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds JNJ's momentum and catalyst factors above.
Tracking JNJ
Johnson & Johnson rates Hold right now, so MELANY is not flagging a fresh entry. Add JNJ to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates JNJ
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Johnson & Johnson's 65/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about JNJ
Is Johnson & Johnson (JNJ) a buy?
As of 2026-10-07, MELANY rated Johnson & Johnson Hold with a composite score of 65/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Johnson & Johnson's MELANY score?
Johnson & Johnson (JNJ) has a MELANY composite score of 65/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the JNJ stock rating calculated?
MELANY scores JNJ from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Johnson & Johnson stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Johnson & Johnson (JNJ) Hold with a composite of 65/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the JNJ stock price forecast?
MELANY does not publish price targets or forecasts for JNJ. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 65/100 across eight factors for Johnson & Johnson, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is JNJ stock overvalued or undervalued?
MELANY's valuation factor currently reads 40/100 for Johnson & Johnson, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives JNJ's read.
What price should I buy JNJ at?
MELANY is not flagging a fresh entry for JNJ at its current Hold rating, so there is no entry zone to publish right now. Add JNJ to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying JNJ stock?
The top risks MELANY currently flags for Johnson & Johnson: Earnings report in 6 days, binary outcome can move 10%+ either way. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Johnson & Johnson a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 82/100 for Johnson & Johnson, and earnings track record, at 68/100. The 65/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will JNJ stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 59/100 for JNJ right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this JNJ rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores JNJ continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, JNJ included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.